OBJECTIVE: Survival of patients diagnosed with advanced-stage high-grade serous ovarian cancer (HGSOC) varies widely. Understanding the biological and molecular differences between tumors associated with short-term and long-term survival may inform prognosis and treatment. METHODS: Omental tumor samples were collected from 15 short-term survivors (STS; <12 months) and 15 long-term survivors (LTS; ≥ 120 months) with stage III-IV HGSOC who underwent primary debulking surgery followed by platinum-based chemotherapy. Bulk tumor sections were analyzed using whole-genome RNA sequencing. Corresponding H INHBA, p < 0.0001) and epithelial-mesenchymal transition markers (ZEB1, p < 0.001; CALD1, p < 0.001), while LTS was enriched for immune signaling pathways. CONCLUSIONS: Omental metastases from STS and LTS patients have distinct molecular and spatial profiles. The enrichment of fibroblast-associated gene signatures in STS and immunoreactive pathways in LTS underscores a divergent tumor microenvironment with potential clinical relevance.
Smick et al. (Sat,) studied this question.